Gary Woodnutt

Senior Vice President at ContraFect Corp - Yonkers, NY, US

Gary Woodnutt's Colleagues at ContraFect Corp
Brittney Smith

Regulatory and Clinical Quality Coordinator

Contact Brittney Smith

Jill Steeley

Clinical Program Manager

Contact Jill Steeley

Brandon Borders

Associate Director of Toxicology

Contact Brandon Borders

Roger Pomerantz

President, CEO and Chairman

Contact Roger Pomerantz

Francine Pisana

Director Clinical Operations

Contact Francine Pisana

Xavier Farres

Associate Director of Research

Contact Xavier Farres

View All Gary Woodnutt's Colleagues
Gary Woodnutt's Contact Details
HQ
914-207-2300
Location
San Diego,California,United States
Company
ContraFect Corp
Gary Woodnutt's Company Details
ContraFect Corp logo, ContraFect Corp contact details

ContraFect Corp

Yonkers, NY, US • 50 - 99 Employees
BioTech/Drugs

We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.

B2B Biotechnology Healthcare Pharmaceuticals BioTech/Drugs Commercial Physical Research
Details about ContraFect Corp
Frequently Asked Questions about Gary Woodnutt
Gary Woodnutt currently works for ContraFect Corp.
Gary Woodnutt's role at ContraFect Corp is Senior Vice President.
Gary Woodnutt's email address is ***@contrafect.com. To view Gary Woodnutt's full email address, please signup to ConnectPlex.
Gary Woodnutt works in the Research industry.
Gary Woodnutt's colleagues at ContraFect Corp are Marina Bass, Brittney Smith, Jill Steeley, Brandon Borders, Roger Pomerantz, Francine Pisana, Xavier Farres and others.
Gary Woodnutt's phone number is 914-207-2300
See more information about Gary Woodnutt